AstraZeneca And Guangzhou Medical College Conduct Pulmonary Disease Study
This article was originally published in PharmAsia News
Executive SummaryAstraZeneca Research Foundation and No. 1 Affiliated Hospital of Guangzhou Medical College have signed an agreement to jointly conduct basic research on chronic obstructive pulmonary disease. This represents the first MNC study on COPD in China. The hospital's national key laboratory of respiratory disease will undertake a two-year study into the reason for the disease's progress by observing 500 patients with COPD and comparing them with healthy controls. In China, COPD has an incidence of 8.4 percent but more than half the patients are not aware of the disease. Experts hope to instil the concept among healthcare workers that COPD is preventable and treatable. (Click here for more - Chinese language)
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.